Jacqueline Chang, MD
Critical Care Medicine · la Jolla, CANPI 1053410027
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 141 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Boehringer Ingelheim at 38.9% of the total. Reporting peaked in 2019 at $1,317 and has fallen 73.6% since, to $348 in 2025.
Across 141 payments — averaging $21.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$1K
- GSK$469
- AstraZeneca$265
- Genentech USA, Inc.$173
- AbbVie$167
- Sunovion Pharmaceuticals Inc.$95
- plus $694 from 17 others
Across 6 payments — averaging $14,071 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$81K
- Biogen$4K
What the payments were for
- Food & beverage$3,050100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 48 | $1,187 |
| GSK | 27 | $469 |
| AstraZeneca(2 entities) | 12 | $265 |
| Genentech USA, Inc. | 9 | $173 |
| AbbVie(2 entities) | 3 | $167 |
| Sunovion Pharmaceuticals Inc. | 8 | $95 |
| Cook Medical LLC | 1 | $94 |
| Merck | 6 | $91 |
| Insmed, Inc. | 4 | $79 |
| Mylan Specialty L.p. | 3 | $68 |
| Philips North America LLC | 3 | $62 |
| United Therapeutics Corporation | 2 | $45 |
| Boston Scientific | 2 | $33 |
| Antares Pharma, Inc. | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Mannkind Corporation | 2 | $25 |
| Gilead | 1 | $24 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| Baxter Healthcare | 1 | $19 |
| Amgen | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Viiv Healthcare Company | 1 | $18 |
| Advanced Respiratory, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,050 in reported general payments places this provider in the 80th percentile of 715 critical care medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 112 | $1,407,845 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 404 | $344,285 |
| Pirfenidone | 87 | $167,003 |
| Spiriva RespimatTiotropium Bromide | 172 | $135,112 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 162 | $99,827 |
| Breo ElliptaFluticasone/Vilanterol | 162 | $84,157 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 110 | $80,607 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 58 | $48,268 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 59 | $36,236 |
| Advair HfaFluticasone Propion/Salmeterol | 75 | $35,387 |
| EliquisApixaban | 39 | $30,009 |
| XareltoRivaroxaban | 27 | $28,597 |
| Arnuity ElliptaFluticasone Furoate | 96 | $26,617 |
| SymbicortBudesonide/Formoterol Fumarate | 69 | $23,428 |
| DuleraMometasone/Formoterol | 39 | $19,690 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $1,187 | $1,623,564394 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $469 | $573,724860 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort, Pulmicort Flexhaler | $265 | $123,108227 claims |
| MerckDulera | $91 | $19,69039 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 715 critical care medicine providers in California.
Other critical care medicine in la Jolla
- Stephen Bradleyla Jolla$85K
- Laura Crotty Alexanderla Jolla$12K
- Cedric Franklin RutlandRiverside$3.2M
- Chinh PhanSacramento$467K
- Timothy AlbertsonSacramento$418K
- Stephen ChenMonterey Park$394K
- Bassam YaghmourOrange$376K
- Xuanha WhiteSan Diego$343K
- Ken YonedaSacramento$173K
- Praveen AkuthotaSan Diego$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.